In this episode, we sit down with Laurence Klein, Co-Founder and CEO of Nuvo, to explore how the FDA cleared INVU™ platform is reshaping maternal fetal surveillance and redefining the standard of care for pregnancy. Laurence traces the company's mission to replace episodic, clinic bound monitoring with continuous, medical grade prenatal care delivered at home or at work — and explains how that vision is now meeting a rapidly expanding commercial market.

We cover:

• The Genesis of Nuvo — How a pregnancy wearable idea became a mission to decentralize prenatal care and put clinical-grade monitoring in the hands of expectant mothers wherever they are.
• The Biosensing Architecture — How INVU™'s passive array of ECG and PCG surface sensors, paired with cloud-based AI, achieves medical-grade fetal monitoring without active ultrasound — and what that means for accuracy, wearability, and scale.
• The Market Opportunity — Why the convergence of rural care gaps, urban lifestyle demands, and remote monitoring is creating a structural shift — not just a product category.
• Capital Strategy & What's Next — Deployment priorities following their Series A, the role of generative data pipelines in expanding clinical intelligence, and what institutional investors should be watching heading into the next growth round.

Essential listening for anyone following the intersection of deeptech medical devices, digital health infrastructure, and AI-driven diagnostics.